BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abdel-rahman SM, Amidon GL, Kaul A, Lukacova V, Vinks AA, Knipp GT. Summary of the National Institute of Child Health and Human Development–Best Pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop–Pediatric Biopharmaceutics Classification System Working Group. Clinical Therapeutics 2012;34:S11-24. [DOI: 10.1016/j.clinthera.2012.09.014] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Del Moral Sanchez JM, Gonzalez-Alvarez I, Cerda-Revert A, Gonzalez-Alvarez M, Navarro-Ruiz A, Amidon GL, Bermejo M. Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system. Br J Clin Pharmacol 2018;84:2231-41. [PMID: 29846973 DOI: 10.1111/bcp.13650] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
2 Jiang XL, Zhao P, Barrett JS, Lesko LJ, Schmidt S. Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children. CPT Pharmacometrics Syst Pharmacol 2013;2:e80. [PMID: 24132164 DOI: 10.1038/psp.2013.55] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 8.9] [Reference Citation Analysis]
3 Debotton N, Dahan A. A mechanistic approach to understanding oral drug absorption in pediatrics: an overview of fundamentals. Drug Discovery Today 2014;19:1322-36. [DOI: 10.1016/j.drudis.2014.03.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
4 delMoral-Sanchez JM, Gonzalez-Alvarez I, Gonzalez-Alvarez M, Navarro A, Bermejo M. Classification of WHO Essential Oral Medicines for Children Applying a Provisional Pediatric Biopharmaceutics Classification System. Pharmaceutics 2019;11:E567. [PMID: 31683740 DOI: 10.3390/pharmaceutics11110567] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
5 Nicolas JM, de Lange ECM. Mind the Gaps: Ontogeny of Human Brain P-gp and Its Impact on Drug Toxicity. AAPS J 2019;21:67. [PMID: 31140038 DOI: 10.1208/s12248-019-0340-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
6 Bhatt-Mehta V, MacArthur RB, Löbenberg R, Cies JJ, Cernak I, Ii RHP. An Algorithm to Identify Compounded Non-Sterile Products that Can Be Formulated on a Commercial Scale or Imported to Promote Safer Medication Use in Children. Pharmacy (Basel) 2015;3:284-94. [PMID: 28975916 DOI: 10.3390/pharmacy3040284] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Guimarães M, Statelova M, Holm R, Reppas C, Symilllides M, Vertzoni M, Fotaki N. Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products - a PEARRL review. J Pharm Pharmacol 2019;71:603-42. [PMID: 29971768 DOI: 10.1111/jphp.12955] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
8 Türkmen Ö, Ay Şenyiğit Z, Baloğlu E. Formulation and evaluation of fexofenadine hydrochloride orally disintegrating tablets for pediatric use. Journal of Drug Delivery Science and Technology 2018;43:201-10. [DOI: 10.1016/j.jddst.2017.10.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
9 Charoo NA, Cristofoletti R, Dressman JB. Risk assessment for extending the Biopharmaceutics Classification System-based biowaiver of immediate release dosage forms of fluconazole in adults to the paediatric population. J Pharm Pharmacol 2015;67:1156-69. [PMID: 25828546 DOI: 10.1111/jphp.12411] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
10 Oostenbrink R, de Wildt SN. Drug trials: Kids are no little adults and not all kids are the same. Journal of Clinical Epidemiology 2016;71:111-2. [DOI: 10.1016/j.jclinepi.2015.06.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
11 Bhatt-Mehta V, Hammoud H, Amidon GL. A proposed pediatric biopharmaceutical classification system for medications for chronic diseases in children. Eur J Pharm Sci 2020;152:105437. [PMID: 32598914 DOI: 10.1016/j.ejps.2020.105437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Kofoed-Djursner C, Jamil A, Selen A, Müllertz A, Berthelsen R. Drug solubilization during simulated pediatric gastro-intestinal digestion. Eur J Pharm Sci 2021;162:105828. [PMID: 33819625 DOI: 10.1016/j.ejps.2021.105828] [Reference Citation Analysis]
13 Li J, Larregieu CA, Benet LZ. Classification of natural products as sources of drugs according to the biopharmaceutics drug disposition classification system (BDDCS). Chin J Nat Med 2016;14:888-97. [PMID: 28262115 DOI: 10.1016/S1875-5364(17)30013-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
14 Rieder M. Size and Taste Matters: Recent Progress in the Development of Age-Appropriate Medicines for Children. Pharm Med 2018;32:21-30. [DOI: 10.1007/s40290-017-0218-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Brussee JM, Calvier EA, Krekels EH, Välitalo PA, Tibboel D, Allegaert K, Knibbe CA. Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling. Expert Rev Clin Pharmacol 2016;9:1235-44. [PMID: 27269200 DOI: 10.1080/17512433.2016.1198256] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
16 Sage DP, Kulczar C, Roth W, Liu W, Knipp GT. Persistent pharmacokinetic challenges to pediatric drug development. Front Genet 2014;5:281. [PMID: 25221567 DOI: 10.3389/fgene.2014.00281] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
17 Batchelor HK, Kendall R, Desset-Brethes S, Alex R, Ernest TB; European Paediatric Formulation Initiative. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients. Eur J Pharm Biopharm 2013;85:833-42. [PMID: 23665448 DOI: 10.1016/j.ejpb.2013.04.015] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
18 Papadatou-Soulou E, Mason J, Parsons C, Oates A, Thyagarajan M, Batchelor HK. Magnetic Resonance Imaging Quantification of Gastrointestinal Liquid Volumes and Distribution in the Gastrointestinal Tract of Children. Mol Pharm 2019;16:3896-903. [PMID: 31373502 DOI: 10.1021/acs.molpharmaceut.9b00510] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
19 Martir J, Flanagan T, Mann J, Fotaki N. BCS-based biowaivers: Extension to paediatrics. Eur J Pharm Sci 2020;155:105549. [PMID: 32941998 DOI: 10.1016/j.ejps.2020.105549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Welisch E, Altamirano-Diaz LA. Ethics of pharmacological research involving adolescents. Paediatr Drugs 2015;17:55-9. [PMID: 25523399 DOI: 10.1007/s40272-014-0114-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Gandhi SV, Rodriguez W, Khan M, Polli JE. Considerations for a Pediatric Biopharmaceutics Classification System (BCS): application to five drugs. AAPS PharmSciTech 2014;15:601-11. [PMID: 24557773 DOI: 10.1208/s12249-014-0084-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
22 Tulloch JSP, Minford S, Pimblett V, Rotheram M, Christley RM, Westgarth C. Paediatric emergency department dog bite attendance during the COVID-19 pandemic: an audit at a tertiary children's hospital. BMJ Paediatr Open 2021;5:e001040. [PMID: 33884313 DOI: 10.1136/bmjpo-2021-001040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
23 Elder DP, Holm R, Kuentz M. Medicines for Pediatric Patients-Biopharmaceutical, Developmental, and Regulatory Considerations. J Pharm Sci 2017;106:950-60. [PMID: 28041968 DOI: 10.1016/j.xphs.2016.12.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
24 Shawahna R. Pediatric Biopharmaceutical Classification System: Using Age-Appropriate Initial Gastric Volume. AAPS J 2016;18:728-36. [PMID: 26935428 DOI: 10.1208/s12248-016-9885-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
25 Rioux N, Waters NJ. Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development. Drug Metabolism and Disposition 2016;44:934-43. [DOI: 10.1124/dmd.115.068031] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
26 Kohlmann P, Stillhart C, Kuentz M, Parrott N. Investigating Oral Absorption of Carbamazepine in Pediatric Populations. AAPS J 2017;19:1864-77. [DOI: 10.1208/s12248-017-0149-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
27 Van Riet-Nales DA, Kozarewicz P, Aylward B, de Vries R, Egberts TC, Rademaker CM, Schobben AF. Paediatric Drug Development and Formulation Design-a European Perspective. AAPS PharmSciTech 2017;18:241-9. [PMID: 27270905 DOI: 10.1208/s12249-016-0558-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
28 Zajicek A, Fossler MJ, Barrett JS, Worthington JH, Ternik R, Charkoftaki G, Lum S, Breitkreutz J, Baltezor M, Macheras P, Khan M, Agharkar S, MacLaren DD. A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms. AAPS J 2013;15:1072-81. [PMID: 23907486 DOI: 10.1208/s12248-013-9511-5] [Cited by in Crossref: 61] [Cited by in F6Publishing: 47] [Article Influence: 7.6] [Reference Citation Analysis]
29 Johnson T, Bonner J, Tucker G, Turner D, Jamei M. Development and applications of a physiologically-based model of paediatric oral drug absorption. European Journal of Pharmaceutical Sciences 2018;115:57-67. [DOI: 10.1016/j.ejps.2018.01.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
30 Batchelor H. Paediatric biopharmaceutics classification system: Current status and future decisions. International Journal of Pharmaceutics 2014;469:251-3. [DOI: 10.1016/j.ijpharm.2014.02.046] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
31 García-arieta A, Gordon J. On the BCS biowaivers of orally disintegrating tablets. European Journal of Pharmaceutical Sciences 2015;66:107-8. [DOI: 10.1016/j.ejps.2014.10.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Maharaj AR, Edginton AN, Fotaki N. Assessment of Age-Related Changes in Pediatric Gastrointestinal Solubility. Pharm Res 2016;33:52-71. [DOI: 10.1007/s11095-015-1762-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
33 Li H, Shi FH, Huang SY, Zhang SG, Chen HW. The best pharmaceuticals for children-what can we do? Transl Pediatr 2020;9:86-92. [PMID: 32477907 DOI: 10.21037/tp.2020.02.07] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Bhatt-mehta V, Macarthur RB, Löbenberg R, Cies JJ, Cernak I, Parrish RH. Development of an algorithm to identify mass production candidate molecules to develop children’s oral medicines: a North American perspective. AAPS Open 2016;2. [DOI: 10.1186/s41120-016-0009-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
35 Lukacova V, Goelzer P, Reddy M, Greig G, Reigner B, Parrott N. A Physiologically Based Pharmacokinetic Model for Ganciclovir and Its Prodrug Valganciclovir in Adults and Children. AAPS J 2016;18:1453-63. [PMID: 27450227 DOI: 10.1208/s12248-016-9956-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
36 Emoto C, Fukuda T, Johnson TN, Adams DM, Vinks AA. Development of a Pediatric Physiologically Based Pharmacokinetic Model for Sirolimus: Applying Principles of Growth and Maturation in Neonates and Infants. CPT Pharmacometrics Syst Pharmacol 2015;4:e17. [PMID: 26225230 DOI: 10.1002/psp4.17] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
37 Batchelor HK, Fotaki N, Klein S. Paediatric oral biopharmaceutics: Key considerations and current challenges. Advanced Drug Delivery Reviews 2014;73:102-26. [DOI: 10.1016/j.addr.2013.10.006] [Cited by in Crossref: 83] [Cited by in F6Publishing: 78] [Article Influence: 11.9] [Reference Citation Analysis]
38 Shawahna R, Zyoud A, Haj-Yahia A, Taya R. Evaluating Solubility of Celecoxib in Age-Appropriate Fasted- and Fed-State Gastric and Intestinal Biorelevant Media Representative of Adult and Pediatric Patients: Implications on Future Pediatric Biopharmaceutical Classification System. AAPS PharmSciTech 2021;22:84. [PMID: 33649887 DOI: 10.1208/s12249-021-01958-3] [Reference Citation Analysis]
39 Singh G, Arora A, Rani S, Maurya IK, Aulakh D, Wriedt M. Heteroaryl chalcone allied triazole conjugated organosilatranes: synthesis, spectral analysis, antimicrobial screening, photophysical and theoretical investigations. RSC Adv 2016;6:82057-81. [DOI: 10.1039/c6ra13949c] [Cited by in Crossref: 9] [Article Influence: 1.8] [Reference Citation Analysis]
40 Zhou H, Shi T, Yan J, Chen X, Liao L, Zhao S, Fang H, Zhuang R. Effects of activated carbon N-acetylcysteine sustained-release microcapsule on dipeptidyl peptidase IV expression in young rats with non-alcoholic fatty liver disease. Exp Ther Med 2017;14:4737-44. [PMID: 29201174 DOI: 10.3892/etm.2017.5128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
41 delMoral-Sanchez JM, Gonzalez-Alvarez I, Gonzalez-Alvarez M, Navarro-Ruiz A, Bermejo M. Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019. Pharmaceutics 2020;12:E316. [PMID: 32244848 DOI: 10.3390/pharmaceutics12040316] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
42 Batchelor H, Ernest T, Flanagan T, Klein S, Turner R, Fotaki N, Storey D; EuPFI. Towards the development of a paediatric biopharmaceutics classification system: Results of a survey of experts. Int J Pharm 2016;511:1151-7. [PMID: 27349792 DOI: 10.1016/j.ijpharm.2016.06.115] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
43 Pawar G, Wu F, Zhao L, Fang L, Burckart GJ, Feng K, Mousa YM, Naumann F, Batchelor HK. Development of a Pediatric Relative Bioavailability/Bioequivalence Database and Identification of Putative Risk Factors Associated With Evaluation of Pediatric Oral Products. AAPS J 2021;23:57. [PMID: 33884497 DOI: 10.1208/s12248-021-00592-y] [Reference Citation Analysis]
44 Cristofoletti R, Charoo NA, Dressman JB. Exploratory Investigation of the Limiting Steps of Oral Absorption of Fluconazole and Ketoconazole in Children Using an In Silico Pediatric Absorption Model. Journal of Pharmaceutical Sciences 2016;105:2794-803. [DOI: 10.1016/j.xphs.2016.01.027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]